Dana Aftab Sells 43,451 Shares of Exelixis (NASDAQ:EXEL) Stock

Exelixis, Inc. (NASDAQ:EXEL) EVP Dana Aftab sold 43,451 shares of the stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $50.35, for a total value of $2,187,757.85. Following the sale, the executive vice president owned 594,741 shares of the company’s stock, valued at $29,945,209.35. This trade represents a 6.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Exelixis Stock Down 1.9%

Shares of NASDAQ EXEL opened at $50.48 on Friday. The stock’s fifty day simple moving average is $46.01 and its 200 day simple moving average is $44.22. The stock has a market capitalization of $12.69 billion, a price-to-earnings ratio of 16.77, a PEG ratio of 1.08 and a beta of 0.38. Exelixis, Inc. has a 52-week low of $33.76 and a 52-week high of $52.96.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Tuesday, May 5th. The biotechnology company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.75 by $0.12. The business had revenue of $610.81 million during the quarter, compared to the consensus estimate of $607.51 million. Exelixis had a return on equity of 39.89% and a net margin of 35.08%.Exelixis’s revenue was up 10.0% compared to the same quarter last year. During the same period in the prior year, the business posted $0.55 earnings per share. As a group, analysts anticipate that Exelixis, Inc. will post 3.18 earnings per share for the current year.

Key Exelixis News

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Zacks Research raised several forward earnings estimates for Exelixis, including Q2 2026, Q3 2026, FY2026, FY2027, and FY2028, suggesting analysts see improving profitability ahead. Zacks Research estimate updates
• Positive Sentiment: Exelixis said management will host fireside chats at upcoming June investor conferences, which can support investor confidence by highlighting strategy, pipeline progress, and commercial execution. Investor conference webcast announcement
• Positive Sentiment: Wall Street commentary and fair-value updates have trended higher, with one article noting a refreshed fair value estimate near $49.65 and broader debate about Exelixis’s growth and competitive position. Fair value target article
• Neutral Sentiment: Shareholders approved the company’s equity plan and board slate at the annual meeting, a routine governance update that removes an overhang but is not a major catalyst on its own. Shareholder approval article
• Neutral Sentiment: Executive Vice President Dana Aftab sold 43,451 shares for about $2.19 million. Insider sales can weigh on sentiment, but this does not necessarily signal a change in the company’s fundamentals. Insider sale filing
• Negative Sentiment: One Zacks note trimmed Q1 2027 EPS estimates slightly and maintained only a Hold rating, showing that not all analysts are turning more bullish. Zacks Hold rating and estimate cut

Institutional Trading of Exelixis

A number of hedge funds have recently made changes to their positions in the stock. Anchor Investment Management LLC lifted its position in Exelixis by 500.0% in the 3rd quarter. Anchor Investment Management LLC now owns 600 shares of the biotechnology company’s stock worth $25,000 after buying an additional 500 shares in the last quarter. Motiv8 Investments LLC purchased a new position in shares of Exelixis during the 4th quarter valued at $26,000. Cassaday & Co Wealth Management LLC purchased a new position in shares of Exelixis during the 1st quarter valued at $27,000. Root Financial Partners LLC acquired a new position in shares of Exelixis in the third quarter worth $28,000. Finally, Western Wealth Management LLC acquired a new position in shares of Exelixis in the first quarter worth $29,000. 85.27% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

EXEL has been the subject of several recent analyst reports. Stifel Nicolaus raised their target price on shares of Exelixis from $44.00 to $47.00 and gave the stock a “hold” rating in a report on Wednesday, May 6th. TD Cowen upped their price target on shares of Exelixis from $51.00 to $55.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Wall Street Zen raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Barclays lifted their price objective on shares of Exelixis from $44.00 to $45.00 and gave the stock an “equal weight” rating in a research report on Monday, April 20th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of Exelixis in a research note on Tuesday, May 19th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $47.35.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.